Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
Portfolio Pulse from
Trevi Therapeutics has announced the pricing of a $50 million underwritten offering, selling 12.5 million shares at $4.00 each. This move is aimed at raising funds for the development of their investigational therapy, Haduvio, targeting chronic cough conditions.
December 16, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Trevi Therapeutics has priced a $50 million underwritten offering, issuing 12.5 million shares at $4.00 each. This capital raise is intended to support the development of Haduvio, their investigational therapy for chronic cough conditions.
The announcement of a $50 million underwritten offering suggests potential dilution of existing shares, which could lead to a short-term negative impact on the stock price. However, the funds raised are intended to support the development of Haduvio, which could be positive in the long term if the therapy proves successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100